|Bid||21.14 x 1100|
|Ask||21.17 x 1400|
|Day's Range||20.56 - 21.25|
|52 Week Range||9.03 - 25.29|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Small-cap stocks are considered riskier than large caps or even mid caps. Of course, this means that smaller stocks have greater potential to make profits for investors. This does not mean that you should buy risky stocks randomly.
Small-caps and large-caps are wildly popular among investors; however, mid-cap stocks, such as Spectrum Pharmaceuticals Inc (NASDAQ:SPPI) with a market-capitalization of US$2.22b, rarely draw their attention. While they are lessRead More...
In the second quarter, Spectrum Pharmaceuticals (SPPI) generated net revenues of $24.2 million compared to $34.3 million in Q2 2017. In the first half of the year, Spectrum Pharmaceuticals reported net revenues of $54.7 million compared to $63.4 million in H1 2017.
On September 6, Spectrum Pharmaceuticals stock closed at $22.25, which is a ~5.70% rise from its close of $21.05 on September 5, 2018. On September 6, Spectrum Pharmaceuticals stock price closed at $22.25, which represents ~146% growth from its 52-week low of $9.03 on September 22, 2017. Spectrum Pharmaceuticals hit its 52-week high of $25.29 on August 27, 2018.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on Sept. 5) Aptinyx Inc (NASDAQ: APTX ) Avanos Medical Inc (NYSE: AVNS ...
The biotech sector notched strong gains last week, capitalizing on the positive overall market sentiment, set in motion by the trade deal between the U.S. and Mexico. Here are a few catalysts that could ...
Investors in Spectrum Pharmaceuticals (SPPI) need to pay close attention to the stock based on moves in the options market lately.
Spectrum (SPPI) reports wider-than-expected loss in the second quarter and misses on revenues. Rolontis successful in second phase III study.
Spectrum Pharma (SPPI) delivered earnings and revenue surprises of -16.67% and -13.79%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Henderson, Nevada-based company said it had profit of 13 cents. Losses, adjusted for one-time gains and costs, came to 21 cents per share. The biotechnology company posted revenue ...
Here are four stocks in biotech, energy and media that are breaking out on news. Endocyte Inc.(ECYT) had a strong session Tuesday, up 81 cents, or 6%, to $14.45 on 1.4 million shares traded. The biopharmaceutical company, which on Monday was added to the Russell 3000 Index, announced that an image from its Phase 2 prostate cancer study was selected as “Image of the Year” by the Society of Nuclear Medicine and Molecular Imaging.
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Achieve Life Sciences Inc (NASDAQ: ACHV ) stock was ...
Spectrum Pharmaceuticals Inc., a U.S. biotech company focused on oncology and hematology, is exploring options including a sale of the business amid takeover interest from other drugmakers, people familiar ...
Small-caps and large-caps are wildly popular among investors, however, mid-cap stocks, such as Spectrum Pharmaceuticals Inc (NASDAQ:SPPI), with a market capitalization of US$2.06B, rarely draw their attention from the investingRead More...
Spectrum (SPPI) reports narrower-than-expected loss in the first quarter and also beat revenues. Rolontis successful in phase III study.